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The leading hypothesis on Alzheimer Disease (AD) is that it is caused by buildup of
the peptide amyloid-β (Aβ), which initially causes dysregulation of synaptic plasticity and
eventually causes destruction of synapses and neurons. Pharmacological efforts to limit
Aβ buildup have proven ineffective, and this raises the twin challenges of understanding
the adverse effects of Aβ on synapses and of suggesting pharmacological means to
prevent them. The purpose of this paper is to initiate a computational approach to
understanding the dysregulation by Aβ of synaptic plasticity and to offer suggestions
whereby combinations of various chemical compounds could be arrayed against it. This
data-driven approach confronts the complexity of synaptic plasticity by representing
findings from the literature in a course-grained manner, and focuses on understanding
the aggregate behavior of many molecular interactions. The same set of interactions is
modeled by two different computer programs, each written using a different programming
modality: one imperative, the other declarative. Both programs compute the same results
over an extensive test battery, providing an essential crosscheck. Then the imperative
program is used for the computationally intensive purpose of determining the effects
on the model of every combination of ten different compounds, while the declarative
program is used to analyze model behavior using temporal logic. Together these two
model implementations offer new insights into the mechanisms by which Aβ dysregulates
synaptic plasticity and suggest many drug combinations that potentially may reduce or
prevent it.
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INTRODUCTION
Alzheimer Disease (AD) is the most prevalent form of dementia
(Whitehouse et al., 2000). Despite decades of intensive basic and
clinical investigation, an effective treatment for AD is still lacking.
Part of the difficulty in developing treatments for AD may be the
sheer complexity of the pathological processes that cause it. The
earliest signs of AD are cognitive impairments including deficits
in memory formation and storage that are caused by disruption
of the processes of synaptic plasticity, which are complex in their
own right. One avenue toward understanding these complex pro-
cesses is to represent, simulate, and analyze them using “process
algebra,” a computational technique that falls under the umbrella
of formal methods in computer science (Monin and Hinchey,
2003). The purpose of this study is to develop an initial com-
putational framework for understanding how various chemical
compounds might aid memory in AD by using formal methods
to simulate the deficits in synaptic plasticity that accompany the
disorder.
The model is based on the amyloid hypothesis, which posits
that AD results from the buildup beyond normative levels of
the peptide amyloid-β (Aβ). The amyloid hypothesis has been
the predominant theory of AD etiology for the past two decades
(Hardy and Selkoe, 2002). Doubts have surfaced concerning
whether Aβ is the ultimate cause of AD in humans (Lee et al.,
2004; Castellani et al., 2009; Mullane and Williams, 2013; Roher
et al., 2013; Tayeb et al., 2013), but recent neuropathologi-
cal research shows that individuals who have high levels of Aβ
postmortem, but do not have soluble forms of Aβ localized to
synapses, did not have prior cognitive impairment (Bjorklund
et al., 2012). This finding is consistent with the results of stud-
ies on non-human animals showing that high Aβ levels cause
abnormalities in synaptic plasticity. In vivo, intracerebroventric-
ular administration of Aβ peptides in rats causes deficits in
experimentally induced synaptic plasticity (Freir et al., 2001),
while transgenic mice that overexpress Aβ show deficits in learn-
ing and memory (Hsiao et al., 1996; Chapman et al., 1999;
Koistinaho et al., 2001; Howlett et al., 2004). The literature docu-
menting the adverse effects on synaptic plasticity of soluble Aβ
applied to synapses in vitro provides some of the data for this
formal-methods model of the effects of Aβ on synaptic plastic-
ity (see subsection Experimental Data on Aβ Effects on Synaptic
Plasticity).
Obviously, prevention of Aβ overproduction would eliminate
the adverse effects of Aβ on synaptic plasticity, and these adverse
effects have indeed been reversed in transgenic mouse AD mod-
els in which Aβ overproduction was reduced pharmacologically
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(Klyubin et al., 2005; Ding et al., 2008; Klyubin et al., 2008; Peng
et al., 2010; Townsend et al., 2010; Balducci et al., 2011; Medina
et al., 2011). Unfortunately, the development of clinically safe
pharmacological means to reduce Aβ in humans remains elusive
(Cho and Kim, 2011; Schenk et al., 2012), and it is therefore of
interest to explore ways to ameliorate the effects of Aβ on synap-
tic plasticity. The Alzheimer Research Forum currently lists over
80 chemical compounds at various stages of clinical evaluation
for AD treatment (http://www.alzforum.org/therapeutics), and
many of these aim to improve synaptic plasticity. The possible
benefits for synaptic plasticity of ten compounds, administered
alone or in combination, will be explored computationally using
the formal-methods model introduced here.
In computer science, formal methods are computational
methods for specifying and analyzing systems (Monin and
Hinchey, 2003). In practice, formal methods are implemented
by creating a model of a system that takes the form of a
computer program written in a declarative programming lan-
guage. Whereas the more conventional, imperative programming
languages are designed for efficient computation and facilitate
intensive simulation of system behavior under many different
circumstances, declarative languages are designed to facilitate
analysis of selected system behaviors via temporal logic (Huth
and Ryan, 2004). Essentially, imperative programs are used to
compute quickly and without keeping track of the sequence of
computations that gave rise to the result. In contrast, declara-
tive programs are slower but they do keep track of the sequences
of computations they execute, and these sequences can later be
searched for specific system states, or queried for evaluation of
temporal-logic properties such as whether or not a specific state
eventually occurs, never occurs, is always present, or present but
only after the occurrence of some other specific state, and so on.
The advantages of declarative programming for modeling and
analysis of biological systems have been recognized, and early
applications have appeared (Fisher and Henzinger, 2007). The
declarative language used here is called Maude (Clavel et al.,
2007). Maude has already been applied in modeling biologi-
cal systems (Eker et al., 2002; Talcott, 2008). Applications of
Maude include recent models of AD etiology (Anastasio, 2011,
2013). These previous publications can be consulted for more
detailed explanations of the declarative programming approach
to understanding biological systems.
Themodel described here is similar in form to the recent mod-
els of AD etiology (Anastasio, 2011, 2013) in that it is data-driven.
As such, experimental findings as reported in the literature are
represented as declarations in a Maude program (a.k.a. specifica-
tion). Like the previous AD models, this model is coarse grained
in that the details of specific molecular interactions are omit-
ted. Only the basic, experimentally observed facts are retained.
Previous authors have noted the huge variability in the experi-
mental preparations that have been used to study synaptic plas-
ticity, including those used to study the effects on it of Aβ (Nistico
et al., 2012). The model developed here does not endeavor to rep-
resent this multitude of experimental configurations. Instead it
adopts a generic framework, and suggests that experiments on
synaptic plasticity in general, and on pharmacological modifica-
tion of plasticity in specific, would be best done using a standard
preparation (see also Discussion). The goal is to gain a high-level
perspective on the interactions occurring within the system of
many molecules that underlies normal synaptic plasticity, and on
how that system is dysregulated by Aβ.
In addition to the declarative Maude specification, the same
system of molecular interactions is also represented in a program
written in MATLAB®, an imperative language. Both programs
behave identically over an extensive test battery, and this cross-
check provides assurance that overall model behavior is consistent
with basic findings on synaptic plasticity and that the results
are not corrupted by programming error. The Maude version
is used to analyze the performance of the model with or with-
out Aβ but in the absence of any pharmacological intervention.
Then the MATLAB version is used to screen for efficacy every one
of the 1024 possible combinations of ten compounds that have
been shown, by themselves, to ameliorate the adverse effects of
Aβ on synaptic plasticity. The Maude version is used to analyze
the mechanisms by which the 20 most efficacious combina-
tions might actually work. The results provide new insights into
how Aβ dysregulates the system of molecular interactions that
underlies synaptic plasticity, and offers predictions concerning
the possible ameliorative effects of 20 combinations of known
compounds, which could be experimentally tested using a stan-
dardized preparation. The main benefits of the approach are that
it represents many findings from the literature and shows what
they imply in the aggregate, and that it provides an initial but rig-
orousmeans to discover possible drug combinations that improve
outcomes over any single-drug therapy.
METHODS
EXPERIMENTAL DATA ON BASIC MECHANISMS OF LTP AND LTD
The two forms of synaptic plasticity most relevant to AD neu-
ropathology are long-term potentiation (LTP) and long-term
depression (LTD), which are long-lasting increases and decreases
in synaptic strength, respectively. The two brain regions most
implicated in AD neuropathology are hippocampus and cere-
bral cortex (Eustache et al., 2000), and the in vitro studies on
Aβ effects on LTP and LTD have been carried out using brain
slices or cultures containing neurons from those two regions. The
basic features of the molecular interactions that underlie LTP and
LTD in hippocampus, frontal cortex, and other brain regions have
been reviewed extensively (Malenka and Bear, 2004; Citri and
Malenka, 2008; Stanton et al., 2010). For reasons of manageability
and tractability of this initial model, it focuses on early, post-
synaptic mechanisms of LTP and LTD that do not require new
protein synthesis. The molecular interactions that mediate these
mechanisms are diagrammed in Figure 1.
The neurotransmitter mediating transmission at most exci-
tatory synapses in hippocampus and cortex is glutamate (Glu),
and the receptor responsible for postsynaptic depolarization is the
α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid recep-
tor (AMPAR). Basically, changes in synaptic strength due to
LTP or LTD involve increases or decreases, respectively, in the
ionic conductance and/or presence in the postsynaptic density of
AMPARs. The best known forms of LTP and LTD are triggered by
activation by Glu ofN-methyl-D-aspartate receptors (NMDARs).
This requires concurrent depolarization of the postsynaptic ter-
minal, which is usually a dendritic spine. Basically, sufficient
depolarization makes it possible for Glu to activate NMDARs,
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FIGURE 1 | Schematic of the data-driven model of the effects of Aβ
on synaptic plasticity. The diagram depicts the influences that each
element has on the other elements in the model. Arrowheads and tees
represent positive and negative influences, respectively. The diagram
was drawn using Graphviz software. The list of abbreviations is
provided in Table 1.
which causes calcium ions (Ca) to flow into the postsynaptic
spine. An intense, brief (several seconds) Ca increase leads to LTP
while a more moderate, prolonged (several minutes) Ca increase
leads to LTD (Yang et al., 1999).
Under natural circumstances, postsynaptic terminal depolar-
ization would be produced by presynaptic activity and release
of Glu onto spine AMPARs, which would cause them to allow
sodium and potassium (but not calcium) ions to enter the spine.
Experimentally, intense/brief or moderate/prolonged stimulation
of presynaptic axons leads to LTP or LTD, respectively. AMPARs
and NMDARs are colocalized on the postsynaptic density of den-
dritic spines via structural proteins such as postsynaptic density
95 (PSD95), and their activation leads to increases within the
spine in cation concentration (sodium, potassium, and calcium,
with calcium flowing through NMDARs only). Increased intra-
spine Ca initiates an array of signal transduction mechanisms
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that contribute to the production of LTP or LTD. Essentially, the
increases or decreases in AMPAR tone associated with LTP or LTD
are driven by signal transductions that result in the activation of
kinases or phosphatases, respectively.
Central to NMDAR-mediated LTP production is the kinase
calcium/calmodulin-dependent protein kinase II (CaMKII),
which is activated by Ca through calmodulin (CaM) (Lisman
et al., 2012). Activated CaMKII potentiates the synapse by phos-
phorylating the AR1 subunit of the AMPAR receptor. This leads
both to increased AMPAR ionic conductance and to increased
AMPAR insertion into and retention by the postsynaptic den-
sity. The exocytotic process involves structural proteins known
as transmembrane AMPAR regulatory proteins (TARPs). Other
kinases also contribute to LTP, including protein kinase A (PKA),
which is activated by cyclic adenosine monophosphate (cAMP)
produced by adenylyl cyclase (AC), which itself is activated by Ca
via CaM (Ferguson and Storm, 2004). PKA boosts CaMKII by
activating phosphoprotein inhibitor 1 (PPI1), which inactivates
protein phosphatase 1 (PP1). Because PP1 and CaMKII aremutu-
ally inhibitory (Strack et al., 1997), PP1 inactivation promotes
CaMKII activation. Protein kinase C (PKC) and sarcoma (Src)
kinase are also involved in LTP production because PKC acti-
vates Src via protein tyrosine kinase 2 (Pyk2) (Dikic et al., 1996),
and Src enhances NMDAR function by phosphorylating the NR2
subunit (Huang et al., 2001). Also, both PKA and PKC phos-
phorylate AR1, leading to increased AMPAR conductance and/or
insertion/retention. The kinases CaMKII, PKA, and PKC inacti-
vate glycogen synthase kinase-3 (GSK3) (Li et al., 2000; Espada
et al., 2009; Song et al., 2010), and this further promotes LTP
because it removes an important contribution to LTD (see below
in this subsection).
Intense presynaptic stimulation also causes secretion of brain-
derived neurotrophic factor (BDNF), which binds to the tyrosine
kinase B (TrkB) receptor and contributes to LTP production
(Minichiello, 2009; Edelmann et al., 2014). Neurotrophin 4
(NT4), which also binds to TrkB, may play a similar role (Xie
et al., 2000). BDNF-mediated LTP is associated with activation
of protein kinase B (PKB, a.k.a. Akt) by phosphoinositide-3-
kinase (PI3K) via phosphoinositide-dependent kinase-1 (PDK1)
(Chan et al., 1999; Kelly and Lynch, 2000; Racaniello et al., 2010).
Binding of BDNF to TrkB activates the insulin receptor substrate
(IRS), and IRS activates PI3K (Yamada et al., 1997). Also, BDNF
binding to TrkB activates the Src homology protein Shc and the
Son of sevenless (SOS) protein, and the activations of IRS, Shc,
and SOS by TrkB are all regulated by growth factor receptor
bound-2 (Grb2) (Buday and Downward, 1993; Rozakis-Adcock
et al., 1993; Skolnik et al., 1993). The activation of SOS may also
require Shc (Minichiello, 2009). SOS then activates the Rat sar-
coma kinase (Ras) (Rozakis-Adcock et al., 1993), and Ras activates
PI3K (Rodriguez-Viciana et al., 1994). Thus, the cascade follow-
ing BDNF binding to TrkB activates PI3K via two pathways. Once
activated, Akt promotes inactivation of GSK3 (Cross et al., 1995;
Peineau et al., 2007). As for CaMKII, PKA, and PKC, Akt pro-
motes LTP by suppressing GSK3 because it removes an important
contribution to LTD (see also below in this subsection).
Central to NMDAR-mediated LTD production is activation by
CaM of protein phosphatase 2B (PP2B, a.k.a. calcineurin), which
activates PP1 by inactivating PPI1 (Mulkey et al., 1994). The CaM
affinity of PP2B is higher than that of CaMKII or AC (Kim et al.,
2010). Thus low levels of Ca lead to activation of the phosphatases
that drive LTD while high levels of Ca are required to activate the
kinases that drive LTP. Phosphatases PP2B and PP1 depress the
synapse by dephosphorylating the AR1 subunit of the AMPAR
receptor, leading to decreased AMPAR ionic conductance and
to increased AMPAR release and removal from the postsynaptic
density. PP1 also contributes to LTD by inhibiting CaMKII, which
is a kinase central to LTP production (see above in this subsec-
tion). PP1 further contributes to LTD by activating GSK3, a kinase
that is actually activated by dephosphorylation (Peineau et al.,
2007). GSK3 in turn promotes PP1 activation through inhibitory
phosphorylation of inhibitor-2 (I2), which inhibits PP1 (Szatmari
et al., 2005). GSK3 contributes to LTD production by phosphory-
lating kinesin light chain-2 (KLC2), which causes KLC2 to release
the AR1 subunit leading to removal of AMPARs from the postsy-
naptic density (Du et al., 2010). Lithium (Li) can suppress LTD
production by inactivating GSK3 (Peineau et al., 2007).
PP2B further contributes to LTD by activating striatal-
enriched protein tyrosine phosphatase (STEP) (Snyder et al.,
2005), and STEP drives LTD in several ways. STEP is most likely
the phosphatase that dephosphorylates the AR2 subunit, leading
to AMPAR removal from the postsynaptic density (Moult et al.,
2006; Zhang et al., 2008). STEP also inactivates Src by inactivating
Pyk2 (Xu et al., 2012). Since Src enhances NMDAR conductance,
STEP reduces Ca flow through NMDARs by this pathway. STEP is
inactivated by PKA (Blanco-Aparicio et al., 1999), which may be
a critical interaction (see Results and Discussion).
Another mechanism by which Glu can induce LTD is through
activation of class I metabotropic glutamate receptors (mGluRs),
of which mGluR5 predominates in hippocampus and cortex
(Anwyl, 2006). This form of LTD can also be evoked using the
class I mGluR agonist dihydroxyphenylglycine (DHPG) (Huang
and Hsu, 2006). Through coupling via the G-protein Gqα, acti-
vation of mGluR5 leads to activation of phospholipase C (PLCγ),
which hydrolyses phosphatidylinositol bisphosphate (PIP2) yield-
ing inositol trisphosphate (IP3) and diacyl glycerol (DAG). IP3
then activates its intracellular receptor IP3R1, which leads to Ca
release from the smooth endoplasmic reticulum. This Ca could
also lead via CaM to activation of phosphatases, as for NMDAR-
mediated LTD. Interestingly, some labs report that mGluR5
activation can lead to phosphatase activation independently of
PLC (Huang and Hsu, 2006; Moult et al., 2006, 2008), but the
mechanism has yet to be identified.
EXPERIMENTAL DATA ON Aβ EFFECTS ON SYNAPTIC PLASTICITY
The Aβ peptide is derived from amyloid precursor protein
through two stages of proteolytic cleavage and occurs in var-
ious lengths with Aβ-40 and Aβ-42 being the most common
(Selkoe, 2001). Although Aβ-42 is more prone to oligomeriza-
tion, both Aβ-40 and Aβ-42 can impair synaptic plasticity after
they self-aggregate into oligomers of low-order (mainly dimers
but possibly also oligomers of up to a dozen Aβ molecules)
(Lambert et al., 1998; Walsh et al., 2002; Townsend et al., 2006;
Shankar et al., 2008). For simplicity in the model, we will consider
the pathogenic agent to be a low-order oligomer of Aβ without
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further distinction. While Aβ at high concentrations is synapto-
toxic (Alberdi et al., 2010), here we focus on exposures to Aβ that
impair synaptic plasticity but do not otherwise damage synapses.
Aβ oligomers suppress LTP but enhance LTD (Wang et al.,
2002; Hsieh et al., 2006; Shankar et al., 2008; Li et al., 2009). Some
of the mechanisms by which Aβ produces these effects on synap-
tic plasticity are known, and many pharmacological interventions
have been suggested (Nistico et al., 2012). The mechanisms of
Aβ-induced synaptic plasticity dysregulation, and putative phar-
macological targets, are also diagrammed in Figure 1.
Aβ can activate α-7 nicotinic acetylcholine receptors
(α7nAChRs), causing them to allow Ca to enter the spine (Wang
et al., 2000; Snyder et al., 2005). This Ca entry leads to activation
of PP2B, which activates STEP, which leads to reduction in
NMDAR Ca conductance (Snyder et al., 2005; Shankar et al.,
2008). Additionally, Aβ may increase STEP levels by inhibiting
the proteosome (Shringarpure et al., 2000; Kurup et al., 2010).
Presumably, these combined mechanisms cause a moderate,
sustained Ca entry into the spine that promotes LTD, and cause
a reduction in NMDAR Ca conductance sufficient to block LTP
even with the strong, brisk presynaptic activity that otherwise
would produce it. Some evidence indicates that Ca entry due
to α7nAChR activation by acetylcholine (ACh) also contributes
to LTP production under normal circumstances, but that this
contribution is stunted by Aβ (Chen et al., 2006).
Acetylcholinesterase inhibitors improve learning and mem-
ory in a transgenic mouse AD model (Dong et al., 2005). Also,
acetylcholinesterase inhibitors prevent LTP suppression due to
Aβ in vivo in a concentration-dependent manner (high doses
of acetylcholinesterase inhibitors actually cause LTP suppres-
sion in control animals) (Kapai et al., 2010, 2012). Nicotine
also prevents learning and memory impairment, and LTP sup-
pression, in an intracerebroventricular-Aβ mouse model of AD
(Srivareerat et al., 2011). These observations of mostly beneficial
effects of α7nAChR activation seem contradicted by the finding
that transgenic AD mice that lack the gene for the α7nAChR
still overexpress Aβ but retain the ability to produce LTP and
have normal learning and memory capability (Dziewczapolski
et al., 2009). It may be that stimulation of α7nAChRs by excess
Aβ both promotes LTD and prevents LTP, but that activation
of α7nAChRs by naturally occurring ACh or by nicotine is not
only consistent with normal synaptic plasticity but can also nor-
malize α7nAChR function despite exposure to excess Aβ. This
possibility is suggested by the findings that the α7nAChR ago-
nist 3-(2,4-dimethoxybenzylidene)-anabaseine (DMXB) reverses
the Aβ-induced LTP deficit (Chen et al., 2006), and that the
α7nAChR partial agonist 2-[2-(4-bromophenyl)-2-oxoethyl]-1-
methyl pyridinium (S 24795) facilitates release of Aβ from
α7nAChRs and restores normal α7nAChR function (Wang et al.,
2009).
The Aβ-induced dysregulation of synaptic plasticity can be
restrained through inhibition of phosphatases. Blockade of PP2B
activity with FK506 or cyclosporin A prevents Aβ-induced LTP
deficits and improves learning andmemory in a transgenic mouse
AD model (Chen et al., 2002; Dineley et al., 2007). Similarly,
blockade of PP1 with tautomycin reverses LTP deficits in trans-
genic mouse AD models (Knobloch et al., 2007). Blockade of
mGluR5s using methyl-6-(phenylethynyl) pyridine (MPEP) also
prevents Aβ-induced LTP suppression (Wang et al., 2004). Note
that some of these and other effects (see below in this subsection)
may be protein-synthesis dependent and so not relevant to the
model, which in its initial form concerns early effects that are not
protein-synthesis dependent (see also Discussion).
LTP is enhanced in transgenic AD mice if they also lack
STEP (Zhang et al., 2010). Resveratrol, a constituent of red
wine, promotes the clearance of Aβ through a mechanism that
involves activation of the proteasome (Marambaud et al., 2005).
Methylene blue also reduces Aβ levels, probably via proteasome
activation, and this is associated with improvement in learning
and memory in a transgenic mouse AD model (Medina et al.,
2011). The benefit is apparently due to reduction in Aβ, but
the improvement in learning and memory also could be due to
increased degradation of STEP by the activated proteasome. Aβ
itself inactivates the proteasome, which causes STEP accumula-
tion, so resveratrol or methylene blue could also reduce STEP
accumulation via proteasome activation.
Aβ impairs both PI3K and Ras activation by TrkB by targeting
the adaptor proteins IRS and Shc (Tong et al., 2004). This prevents
suppression of GSK3 by Akt, and active GSK3 promotes LTD
and prevents LTP. Inhibition of GSK3 using the specific inhibitors
AR-A014418 or CT-99021 blocks Aβ-induced prevention of LTP
(Jo et al., 2011; Shipton et al., 2011). Also, stimulation of TrkB
receptors using BDNF or NT4 reverses Aβ-induced suppression
of LTP (Zeng et al., 2010), and the small-molecule TrkB agonist
7,8-dihydroxyflavone (7,8-DHF) can reduce learning and mem-
ory deficits in a transgenic mouse AD model (Devi and Ohno,
2012).
As an alternative to blocking phosphatases, the Aβ-induced
LTP deficit can also be reduced by treatments that promote
kinase activity. PKA, a kinase that contributes to LTP produc-
tion, is activated by cAMP, and cAMP is activated by AC (see
subsection Experimental Data on Basic Mechanisms of LTP
and LTD). Treatment using forskolin, which activates AC and
thereby increases cAMP and PKA activation, can prevent Aβ-
induced LTP suppression in the hippocampal slice (Vitolo et al.,
2002). Similarly, phosphodiesterase (PDE) breaks down cAMP,
and so would reduce PKA activation and also reduce its LTP
contribution, but treatment using the PDE inhibitor rolipram
both prevents Aβ-induced LTP suppression in the hippocampal
slice and reduces LTP deficits in a transgenic mouse AD model
(Vitolo et al., 2002; Gong et al., 2004). Activation of PKC using
the membrane-permeable PKC agonist phorbol 12-myristate 13-
acetate (PMA) also prevents the Aβ-induced LTP deficit (Zhang
et al., 2009). Interestingly, inactivation of PKC using the PKC
antagonist chelerythrine does not exacerbate the Aβ-induced LTP
deficit.
Although Aβ oligomers bind prion protein, such binding is
not involved in Aβ effects on memory (Balducci et al., 2010).
In fact, recently it has been shown in vivo and in vitro that,
by binding Aβ, prion protein may actually inhibit its deleteri-
ous effects on synapses (Fluharty et al., 2013). Other known
interactions of Aβ with receptors or signaling molecules that are
not directly relevant to early LTP and LTD production are also
excluded from the model. However, even with its sharp focus,
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the initial model has over 50 elements, and the consequences of
their interactions would be almost impossible to determine from
inspection of the model diagram alone (see Figure 1). The model
diagram graphically illustrates the complexity of the problem to
be faced in developing pharmacological means to prevent Aβ-
induced dysregulation of synaptic plasticity, and the likelihood
that this complex problem will require a complex, multitarget
solution has been recognized (Nistico et al., 2012). The purpose
of the initial model is to begin to represent, simulate, and analyze
the interactions computationally, and to initiate a more rational
approach to the design of multidrug treatments for the cognitive
impairment due to AD.
COMPUTATIONAL REPRESENTATION, SIMULATION, AND ANALYSIS
The interactions described above in subsections Experimental
Data on Basic Mechanisms of LTP and LTD and Experimental
Data on Aβ Effects on Synaptic Plasticity are represented com-
putationally both in a Maude specification and in a MATLAB
program. These two computational representations were tested
for equivalence using a test battery that is a superset of the
reported results, and their behavior over the whole battery is the
same (see also Results). In addition to providing a crosscheck,
the two representations offer distinct benefits: the Maude spec-
ification facilitated temporal-logic analysis of the model, while
the MATLAB program facilitated the screening for efficacy of all
possible combinations of ten pharmacological compounds.
The model contains 58 elements, each of which represents a
different molecular species and is associated with a non-negative-
integer level of activity that takes into account both the efficacy
of individual molecules and the abundance of molecules of that
species. For simplicity, many elements are restricted to levels of
0 or 1, so they are essentially binary. These integer (or in many
cases binary) levels are not meant as precise measurements but
have meaning in their changes relative to one another, and they
reflect the statistically significant but otherwise qualitative data
on which they are based. Each element is represented by an
operator in Maude, which assigns to it an integer level, or sim-
ply by a variable in MATLAB. To distinguish them from actual
molecules, and to emphasize that they take relative, integer lev-
els, all model elements are rendered in monotype font using the
name they are given in the computer programs. Because the pro-
gramming languages do not allow Greek lettering, the variable
names are different from standard abbreviations (see Table 1 for a
list of abbreviations). As an example of an element/operator level
assignment, Aβ at level 1 would be written as Abeta(1).
All of the interactions in the model are based on experimen-
tal observations (see subsections Experimental Data on Basic
Mechanisms of LTP and LTD and Experimental Data on Aβ
Effects on Synaptic Plasticity), and some parameters (see below
in this section) are set in order to bring the behavior of the
model in line with empirical findings on LTP and LTD in the
absence or presence of Abeta. Specifically, the model is arranged
so that synaptic strength, which is represented by postsynap-
tic AMPAR, takes levels consistent with baseline conditions, LTP,
or LTD, depending on the prevailing conditions of presynap-
tic activity (preSYN) and Abeta. For simplicity, presynaptic
activity is limited to four levels: preSYN(0), preSYN(1),
Table 1 | List of abbreviations.
Abbreviation Full name
Abeta Amyloid-β (Aβ)
AC Adenylyl cyclase
ACact A compound that activates AC
ACh Acetylcholine
AChRnorm A compound that normalizes the function of the nAChR
Akt Ak thymoma kinase, also known as protein kinase B
AMPAR α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor
AR1 AMPAR subunit 1
AR2 AMPAR subunit 2
BDNF Brain-derived neurotrophic factor
Ca Calcium
cAMP Cyclic adenosine monophosphate
CaM Calmodulin
CaMKII Calcium/calmodulin-dependent protein kinase II
DAG Diacyl glycerol
Glu Glutamate
Gq G-protein q
Grb2 Growth factor receptor bound-2
GSK3 Glycogen synthase kinase-3
GSK3block A compound that blocks GSK3
I2 Inhibitor-2
IP3 Inositol trisphosphate
IP3R1 IP3 intracellular receptor 1
IRS Insulin receptor substrate
KLC2 Kinesin light chain-2
mGluR5 Metabotropic glutamate receptor-5
mGRblock A compound that blocks mGluR5
nAChR Nicotinic acetylcholine receptor
NMDAR N-methyl-D-aspartate receptor
NR1 NMDAR subunit 1
NR2 NMDAR subunit 2
PDE Phosphodiesterase
PDEblock A compound that blocks PDE
PDK1 Phosphoinositide-dependent kinase-1
PI3K Phosphoinositide-3-kinase
PIP2 Phosphatidylinositol bisphosphate
PKA Protein kinase A
PKC Protein kinase C
PKCact A compound that activates PKC
PKCblock A compound that blocks PKC
PLC Phospholipase C
PP1 Protein phosphatase-1
PP1block A compound that blocks PP1
PP2B Protein phosphatase-2B
PP2Bblock A compound that blocks PP2B
PPI1 Phosphoprotein inhibitor-1
proACT A compound that activates the proteosome
proteosome Proteosome
PSD95 Post-synaptic density-95
Pyk2 Protein tyrosine kinase-2
Ras Rat sarcoma kinase
Shc Src homology protein
SOS Son of sevenless
Src Sarcoma kinase
STEP Striatal-enriched protein tyrosine phosphatase
TARP Transmembrane AMPAR regulatory protein
TrkB Tyrosine kinase-B receptor
TrkBnorm A compound that normalizes the function of TrkB
All abbreviations correspond to elements of the Aβ-synapse computer model
and, for that reason, are written in monotype font.
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preSYN(2), and preSYN(3). Aβ is either present or absent:
Abeta(0) or Abeta(1). The normal baseline AMPAR level
is set to 3: AMPAR(3). Normal LTD and LTP are set, respec-
tively, as changes down or up by 3 from baseline: AMPAR(0)
or AMPAR(6). Certain pharmacological interventions can alter
the AMPAR baseline (see Results), but in all cases LTD and LTP
are defined respectively as decreases or increases in AMPAR level
relative to baseline. Then, before any pharmacological interven-
tions are made, the model is set as follows. In the absence of
Abeta [i.e., Abeta(0)], AMPAR takes the baseline level of 3
for preSYN(0) and preSYN(1), takes the LTD level of 0 for
preSYN(2), and takes the LTP level of 6 for preSYN(3). In
the presence of Abeta [i.e., Abeta(1)], AMPAR also takes the
baseline level of 3 for preSYN(0) but takes the LTD level of 0 for
both preSYN(1) and preSYN(2) to reflect the enhancement
of LTD due to Aβ, and takes the baseline level of 3 at preSYN(3)
to reflect the suppression of LTP due to Aβ, as observed exper-
imentally (see subsection Experimental Data on Aβ Effects on
Synaptic Plasticity).
The rest of theMethods section is a concise but precise descrip-
tion of the interactions as they are implemented in the Maude
and MATLAB computer programs. The detail of the description
is sufficient for full program reproduction (readers not interested
in this level of detail can skip the rest of Methods). The descrip-
tion begins with the input elements, which are those whose level
is not influenced by the other (i.e., non-input) elements. Input
elements include Abeta, the neurotransmitters Glu and ACh,
and the neuromodulator BDNF. The levels of Glu and ACh are
equal to the level of preSYN (i.e., 0, 1, 2, or 3). The BDNF level
is 1 if preSYN exceeds the BDNF threshold (BDNFthr) and 0
otherwise. BDNFthr is set at 2.
For simplicity, postsynaptic depolarization is not represented
explicitly but is assumed to occur for any level of preSYN greater
than 0. Also for simplicity, and except for AMPAR, the level of a
neurotransmitter receptor in the model represents the amount of
spine Ca it admits. The level of NMDAR is equal to the sum of
Glu and the levels of its subunits NR1 and NR2 except when Glu
is 0, in which case NMDAR is also 0. NR1 and NR2 are both 1 but
the level of NR2 is augmented to 2 if Src is greater than 0. The
level of mGluR5 is 1 when Glu is greater than 0 and 0 otherwise.
These levels are independent of Abeta. For Abeta(0) the level
of nAChR is equal to ACh, but for Abeta(1) it is 1 when ACh is
0 and 2 when ACh is greater than 0. The neuromodulator receptor
TrkB takes the same level as BDNF. Shc and IRS take the same
level as TrkB, while SOS takes the same level as Shc.
Most non-input elements that receive a positive connection
from only one other element simply take the same level as that
other element. For example, Gq takes mGluR5, CaM takes Ca,
IP3R1 takes IP3, Src takes Pyk2, and so on. Three elements
receive two positive connections: PI3K takes Ras or IRS, while
IP3 and DAG take PLC but only if PIP2 is 1. The level of Ca,
which receives three positive connections, is simply the sum of
NMDAR, nAChR, and IP3R1. The level of Pyk2, which receives a
positive and a negative connection, is the difference between PKC
and STEP, bounded at 0. Note that the results of all subtractions
in the model are bounded at 0 so that all levels are non-negative
integers. Some inhibitory elements are constitutively active at 1
unless they themselves are inhibited, in which case they are 0.
Thus, PPI1 is 1 unless PKA is 0 and PP2B is 1, I2 is 1 but only
if GSK3 is 0, and PP1 is 1 but only if PPI1 and I2 and CaMKII
are all 0. The proteosome is 1 but only if Abeta is 0. The level of
cAMP is 2 plus the difference between AC and PDE unless AC is 0,
in which case cAMP is 0. PDE is 1 unless blocked by PDEblock
(see below in this subsection).
Themost complicated elements are GSK3, STEP, and AMPAR.
GSK3 takes level 1 but this level is augmented to 2 if PP1 is 1.
However, if the kinases that inactivate GSK3 are all fully active
(i.e., PKA is 2, and Akt, PKC, and CaMKII are 1) then GSK3
is 0. Also, if Akt is 1 but the other kinases are not fully active
then GSK3 is the sum of 1 and PP1minus the sum of Akt and
the minimum of PKA and 1. If the proteosome is 1 then STEP
is PP2B minus PKA, but if the proteosome is 0 then STEP
is the sum of PP2B and 1minus PKA. Regardless of PP2B and
PKA, if the proteosome is 2 then STEP is 0. The AMPAR level,
which determines synaptic strength in the model, is the sum of
the levels of its constituents AR1, AR2, and KLC2. AR1 is the
sum of PP1 and PP2B, subtracted from the sum of 1, CaMKII,
PKC, and PKC minus 1. AR2 is 1minus STEP, while KLC2 is
2minus GSK3. These more complicated arrangements, which are
not inconsistent with observations as reported, were made to help
bring the model into agreement with the data (see above in this
subsection).
Bringing themodel into agreement with the data was also facil-
itated by making several key elements binary with thresholds.
Thus, PKC is 1 if Ca exceeds PKCthr. PP2B is 1 if CaM exceeds
PP2Bthr, AC is 1 if CaM exceeds ACthr, and CaMKII is 1 if
CaM exceeds CaMKthr (in which case PP1 is 0). Otherwise these
elements are 0. The thresholds PP2Bthr, ACthr, PKCthr, and
CaMKthr are set at 5, 7, 8, and 9, respectively. The thresh-
olds were set manually in order to bring the model in line with
empirical observation (see above in this subsection).
Input elements also include those representing compounds
that can modify the function of receptors or signaling molecules.
Consistent with findings that certain compounds can normalize
nAChR function by displacing Aβ (see subsection Experimental
Data on Aβ Effects on Synaptic Plasticity), AChRnorm restores
the normal relationship between nAChR and ACh in the presence
of Abeta in the model. Similarly, TrkBnorm restores the nor-
mal functioning of TrkB. In contrast, mGRblock is meant as a
non-competitive inhibitor that simply sets mGluR5 to 0 whether
Abeta is present or absent. The inhibitors GSK3block,
PDEblock, PKCblock, PP1block, and PP2Bblock like-
wise set the level of their associated enzyme to 0. ACact sets AC
to 1 under all circumstances but PKCact sets PKC to 1 only if
PKCblock is 0. The proteosome is set to 2 by proACT.
The interactions described above in this subsection completely
specify the Aβ-synapse model, which was implemented both
as Maude and MATLAB programs. Maude and MATLAB are
fundamentally different. InMATLAB, which is an imperative pro-
gramming language, statements are commands that execute in
strict order but in Maude, which is a declarative language, state-
ments are descriptions of facts that execute in arbitrary order as
they apply (Monin and Hinchey, 2003; Huth and Ryan, 2004;
Clavel et al., 2007). To make their processing modes somewhat
more similar, the interactions in the MATLAB program were
expressed as conditionals within a while loop. The conditional
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for any element took account of the levels of all other relevant
elements and set an update flag if the level of its element was
updated. The while loop continued until no further updates could
be made, at which point the while loop terminated. Execution ter-
minated for all combinations of inputs, which indicates that the
model as implemented in MATLAB always reached a steady-state.
The interactions in the Maude specification were expressed
as a conditional declaration for each element that likewise took
account of the levels of all other relevant elements, and executed
only if the level of its element was changed in so doing. In Maude,
declarations are either “equations” or “rules,” and all applicable
equationsmust execute before any rule can execute (for full details
see Clavel et al., 2007). In the Maude specification for the Aβ-
synapse model, the declarations for STEP and NR2 were rules; all
others were equations. For the purposes of temporal-logic model
checking, Maude executes applicable rules in all possible orders
(see also Huth and Ryan, 2004). Expressing the declarations for
STEP and NR2 as rules imposed a necessary ordering (i.e., the
rules went last) and facilitated checking of the Aβ-synapse model
(see Results). Like the MATLAB program, the Maude specifica-
tion terminated for all combinations of inputs, meaning that the
model as implemented in Maude always reached a steady state.
Despite the programming style adopted for the MATLAB ver-
sion, the Maude and MATLAB versions of the Aβ-synapse model
still employed different processing modes, yet their behavior was
identical over an extensive test battery that was a superset of the
results reported in the next section.
RESULTS
All of the results reported in this section are the same for both
the MATLAB and Maude versions of the Aβ-synapse model. This
crosscheck provides assurance that the reported results are free of
programming error. The MATLAB and Maude versions offered
distinct advantages. Specifically, the MATLAB version was used to
evaluate efficiently the effects of all possible combinations of ten
specific compounds on LTD and LTP in the presence of Abeta,
while the Maude version was used to analyze model behavior in
terms of temporal-logic.
MODEL BEHAVIOR UNDER NORMAL CONDITIONS AND IN THE
PRESENCE OF Aβ
Under normal circumstances in the model [i.e., with
Abeta(0)], LTD is produced at preSYN(2) and LTP
is produced at preSYN(3), each by a distinct pattern of
kinase/phosphatase activation and inactivation. Table 2 shows
the activity of a subset of the kinases and phosphatases that are
integral to the production of LTD and LTP (Table 3 includes
some additional ones). Although they are under the control of a
complex set of interactions, the specific kinase/phosphatase pat-
tern that occurs at any level of presynaptic activity is determined
by the level of Ca produced by that activity. With Abeta(0),
AMPAR is at its baseline level of 3 both for presynaptic activity
levels of 0 or 1 [preSYN(0) or preSYN(1)], and in both cases
the kinase GSK3 is at its constitutive level of 1 but the kinases
PKA, PKC, and CaMKII are at level 0 and the phosphatases
PP2B and PP1 are likewise at level 0 (Table 2 Rows 1 and 2).
With Abeta(0) and preSYN(2) the LTD pattern occurs,
which is characterized by phosphatase activation and kinase
inactivation except for the pro-LTD kinase GSK3, which assumes
level 2 (Table 2 Row 3). With Abeta(0) and preSYN(3) the
LTP pattern occurs, which is characterized by PP1 inactivation
(PP2B stays active) and kinase activation (PKA at 2, PKC and
CaMKII each at 1) except for GSK3, which assumes level 0
(Table 2 Row 4). These kinase/phosphatase patterns characterize
normal LTD and LTP in the model.
In the presence of Abeta [i.e., Abeta(1)], and in
the absence of any pharmacological compounds that modify
receptors or signaling molecules, the LTD pattern occurs at
preSYN(2) but also, aberrantly, at preSYN(1), thus enhanc-
ing LTD by expanding its range (Table 2 Rows 6 and 7). In
contrast, with Abeta(1) the normal LTP pattern does not
occur at preSYN(3) but the LTD pattern does not occur either.
Instead, the activation of PKA thwarts the full LTD pattern and
keeps the AMPAR level at baseline [i.e., AMPAR(3)], mainly
through inhibition by PKA of key LTD drivers (see subsection
Effects of Compounds that Modify Signaling Molecules). The
kinase/phosphatase pattern that pertains with Abeta(1) and
preSYN(3) appears as a hybrid between the normal LTD and
LTP patterns (Table 2 Row 8). The mechanisms by which the
Aβ-synapse model produces this behavior are revealed through
temporal-logic model checking using the Maude specification.
The results of temporal-logic checking of the Aβ-synapse
model are summarized in Table 3. In the absence of Abeta [i.e.,
Abeta(0)], presynaptic activity at level 1 [preSYN(1)] does
not increase Ca enough to cause LTD because the phosphatases
PP2B and PP1 are never activated and the pro-LTD kinase GSK3
is never raised from its constitutive level of 1 to level 2 (Table 3
Rows 1 and 2). LTD occurs (i.e., AMPAR is driven down to level
0) at presynaptic activity level 2 [preSYN(2)], but not until the
phosphatases PP2B, PP1 and, additionally, STEP are activated
and GSK3 attains level 2 (Table 3 Row 3). During the processes of
LTD the pro-LTP kinases PKA, PKC, CaMKII and, additionally,
Akt are never activated (Table 3 Row 4).
Again without Abeta [i.e., Abeta(0)], LTP occurs (i.e.,
AMPAR is brought up to level 6) at preSYN(3) but not until the
kinase PKA reaches level 2 and the other pro-LTP kinases PKC,
CaMKII, and Akt are active at level 1 (Table 3 Row 5). Further
analysis shows that this is not always the case for Abeta(0)
and preSYN(3), but that activation of CaMKII requires prior
activation of Src (Table 3 Rows 6–9). This indicates that the Ca
level does not cross the CaMKII threshold until Src is activated.
Thus, closure of the Src loop, with increased Ca influx through
the NMDAR, is critical for full LTP expression in the model.
At the presynaptic activity level of 0 [preSYN(0)] the
kinase/phosphatase pattern is the same in the presence or absence
of Abeta (Table 3 Rows 10 and 1), but LTD occurs aberrantly
at preSYN(1) with Abeta(1) because Ca is high enough
to bring the phosphatases PP2B, PP1, and STEP, and the
kinase GSK3, into the LTD pattern (Table 3 Rows 11 and 12).
In contrast, with Abeta(1), presynaptic activity at level 3 [i.e.,
preSYN(3)] is not sufficient to raise Ca enough to elicit the full
LTP kinase activation pattern (Table 3 Row 13). However, with
Abeta(1), preSYN(3) does raise Ca high enough to bring
PKA to level 2 (Table 3 Row 14), and this thwarts LTD through
inactivation of PP1 and STEP and return of GSK3 to its con-
stitutive level of 1 by the actions of PKA (see subsection Effects
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of Compounds that Modify Signaling Molecules). Still, the rise in
Cawith Abeta(1) and preSYN(3) is not high enough to acti-
vate any of the other kinases in addition to PKA that are necessary
for LTP (Table 3 Row 15).
EFFECTS OF COMPOUNDS THAT MODIFY RECEPTOR FUNCTION
Dysregulation of synaptic plasticity due to Abeta occurs primar-
ily because Abeta alters Ca influx through the nAChR and also
blocks signal transduction by the TrkB receptor in the model.
Therefore, compounds that restore normal receptor functioning
in the model can offset the dysregulatory effects of Abeta. In
the presence of Abeta [i.e., Abeta(1)], AChRnorm by itself
normalizes LTD and almost fully restores LTP (Table 4 Row 2).
It does this because it normalizes Ca levels at all preSYN lev-
els. At preSYN(3) with AChRnorm(1), PKA and PKC are
always active and CaMKII eventually becomes active. However,
Abeta(1) still causes TrkB signaling failure, with consequent
failure to activate Akt and failure to inactivate GSK3. LTP is not
fully restored because GSK3 is still able to reduce the AMPAR
level through impairment of the normal function of KLC2.
Administration of AChRnorm in combination with TrkBnorm
rectifies this situation and fully restores LTP while also normaliz-
ing LTD (Table 4 Row 6). TrkBnorm by itself does not diminish
the LTD enhancement due to Abeta(1) but it partially restores
LTP at preSYN(3) by allowing TrkB activation by BDNF and
consequent activation of Akt and inactivation of GSK3 (Table 4
Row 4).
mGRblock by itself with Abeta(1) normalizes LTD but
converts LTP to a full LTD (Table 4 Row 3). It does this because
it blocks the mGluR5-induced opening of intracellular Ca stores
and reduces Ca by 1 at all levels of preSYN except preSYN(0),
at which level mGluR5 would not be active anyway. The reduc-
tion by 1 of Ca level due to mGRblock prevents the pattern of
activation of PP2B, PP1, STEP, and GSK3 that supports LTD at
preSYN(1) but allows it at preSYN(2) (see also Table 3). At
preSYN(3) the reduction in Ca level due to mGRblock exac-
erbates the reduction due to Abeta, which is already enough to
prevent the pattern of activation of PKA, PKC, CaMKII, and Akt
that supports LTP. Furthermore, reduction of the Ca level due
to mGRblock also prevents the activation of PKA that would
otherwise thwart LTD at preSYN(3) in the presence of Abeta
(Table 2 Row 8), and allows the kinase/phosphatase pattern that
Table 2 | Model element levels at different levels of presynaptic activity.
Row preSYN Abeta Ca PP2B PP1 GSK3 PKA PKC CaMKII NMDAR AMPAR Effect
1 0 0 0 0 0 1 0 0 0 0 3 None
2 1 0 5 0 0 1 0 0 0 3 3 None
3 2 0 7 1 1 2 0 0 0 4 0 LTD
4 3 0 10 1 0 0 2 1 1 6 6 LTP
5 0 1 1 0 0 1 0 0 0 0 3 None
6 1 1 6 1 1 2 0 0 0 3 0 LTD
7 2 1 7 1 1 2 0 0 0 4 0 LTD
8 3 1 8 1 0 1 2 0 0 5 3 None
Abeta is present for rows 1–4 but absent for rows 5–8. The same results are obtainable with the MATLAB or Maude versions of the Aβ-synapse model.
Table 3 | Results of temporal-logic model checking in the absence or presence of Abeta.
Row preSYN Abeta Proposition Value
1 0 0 PP2B and PP1 and STEP and PKA and PKC and CaMKII and Akt are always 0 and GSK3 is always 1 True
2 1 0 PP2B and PP1 and STEP and PKA and PKC and CaMKII and Akt are always 0 and GSK3 is always 1 True
3 2 0 AMPAR is not 0 until PP2B and PP1 and STEP are 1 and GSK3 is 2 True
4 2 0 PKA and PKC and CaMKII and Akt are always 0 True
5 3 0 AMPAR is not 6 until PKA is 2 and PKC and CaMKII and Akt are 1 True
6 3 0 PKA is always 2 and PKC and CaMKII and Akt are always 1 False
7 3 0 PKA is always 2 and PKC and Akt are always 1 True
8 3 0 CaMKII is eventually 1 True
9 3 0 CaMKII is not 1 until Src is 1 True
10 0 1 PP2B and PP1 and STEP and PKA and PKC and CaMKII and Akt are always 0 and GSK3 is always 1 True
11 1 1 PP2B and PP1 and STEP and PKA and PKC and CaMKII and Akt are always 0 and GSK3 is always 1 False
12 1 1 PP2B and PP1 are eventually 1 and GSK3 and STEP are eventually 2 True
13 3 1 PKA is eventually 2 and PKC and CaMKII and Akt are eventually 1 False
14 3 1 PKA is always 2 True
15 3 1 PKC or CaMKII or Akt are eventually 1 False
The Maude version of the Aβ-synapse model is used for this purpose.
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supports LTD instead. Thus mGRblock does not reduce the
expansion of the LTD range due to Abeta but pushes it to a
higher level of presynaptic activity.
Combined administration of mGRblock and AChRnorm
together with Abeta(1) (Table 4 Row 5) produces less normal-
ization of synaptic plasticity than administration of AChRnorm
alone (Table 4 Row 2) because mGRblock lowers Ca enough at
preSYN(3) to prevent LTP. However, the extension of LTD to
preSYN(3) due to mGRblock alone (Table 4 Row 3) is pre-
vented by AChRnorm when combined with mGRblock (Table 4
Row 5). This occurs at preSYN(3) because the Ca level with
AChRnorm(1) and mGRblock(1) is not enough to activate
PKC or CaMKII but is enough to activate PKA, and this effec-
tively cancels LTD (see next subsection). As explained above,
TrkB activation due to TrkBnorm by itself can augment LTP
by 1, and it also does so in conjunction with mGRblock (Table 4
Row 7) or with AChRnorm and mGRblock (Table 4 Row 8).
EFFECTS OF COMPOUNDS THAT MODIFY SIGNALING MOLECULES
The effect of PKCblock with Abeta(0) (i.e., in the absence
of Abeta) and with preSYN at (0, 1, 2, 3) is AMPAR at (3, 3,
0, 4), which is normal LTD but impaired LTP. So PKC makes a
substantial contribution to LTP in the model but does nothing
to hinder LTD. The effect of PKCblock with Abeta(1) (i.e.,
in the presence of Abeta) and with preSYN at (0, 1, 2, 3) is
AMPAR at (3, 0, 0, 3), which is no change in the synaptic plas-
ticity dysregulation due to Abeta. Thus, blocking PKC does not
improve plasticity, but it does not exacerbate the Abeta impair-
ment of LTP either. This reproduces experimental findings and
suggests that PKA, rather than PKC, is what keeps the synapse at
least at baseline in the presence of Aβ at high levels of presynap-
tic activity and prevents the further expansion of LTD into the
presynaptic-activity range that normally evokes LTP. More gener-
ally, the model suggests that PKA plays a central role in synaptic
plasticity by allowing LTD as Ca is increased, but then by blocking
LTD and allowing LTP as Ca is further increased. The mechanism
may involve AC, which is activated by Ca via CaM and then acti-
vates PKA via cAMP. If the activation threshold for AC is relatively
high, as experimental data suggests it is (Kim et al., 2010), then
AC would only activate PKA at the high Ca levels that should nor-
mally evoke LTP, after which PKA would inhibit STEP, PP1, and
GSK3, which are critical drivers of LTD. The subset of interactions
involved in LTD suppression by PKA is highlighted in Figure 2
(see also Discussion).
ACact does not improve LTP by itself, nor is there any combi-
nation of ACact with other signaling compounds that improves
LTP with Abeta(1). The effect of ACact in the model is to
ensure that AC is active even if CaM is below ACthr, and this
maintains cAMP at a high level and ensures that PKA is always
active. In the model, PKA plays a critical role by canceling LTD
at preSYN(3) with Abeta(1). By keeping PKA always active,
ACact reduces LTD at preSYN(1), which moves plasticity
toward normal, but impairs LTD at preSYN(2), which is abnor-
mal. ACact administered by itself in the model does not prevent
the LTP suppression due to Abeta at preSYN(3). This makes
AC an unsuitable target for normalizing synaptic plasticity with
Abeta(1) in the model. PDEblock boosts PKA activity more
flexibly because it does so only when CaM is above ACthr, and
PDE seems to be a better drug target than AC for normalization
of synaptic plasticity (see below in this subsection).
PP2Bblock by itself and several combinations of
PP2Bblock with other signaling compounds improve
LTP, but all of them do so by completely eliminating LTD at
preSYN(1) and preSYN(2) and some even cause a small
LTP at preSYN(2). In the model, PP2B plays a critical role
by supporting LTD, but this also makes PP2B an unsuitable
target for normalizing synaptic plasticity in the presence of
Abeta. Unlike both ACact and PP2Bblock, there are several
combinations of GSK3block and other signaling compounds
that can improve LTP and reduce LTD enhancement, either
by reducing the amount of LTD equally at both preSYN(1)
and preSYN(2), or by shifting LTD to a lower level (see
below in this subsection). However, in all cases the inclusion of
GSK3block in the mix increases AMPAR baseline but does not
increase the relative, normalizing effects on LTP or LTD over that
which can be achieved using other combinations of compounds.
With AC, PP2B, and GSK3 excluded as drug targets, themodel
suggests that PDE, PKC, PP1, and the proteosome might be
more suitable as drug targets for the normalization of synaptic
plasticity in the presence of Aβ. Table 5 lists some combinations
of signaling molecule modification compounds and their effects
on synaptic plasticity with Abeta(1) in the model.
Table 4 | Effects on synaptic plasticity of compounds that modify receptor function.
Row preSYN AChRnorm mGRblock TrkBnorm AMPAR Effect
1 (0, 1, 2, 3) 0 0 0 (3, 0, 0, 3) Abeta dysregulation: LTD enhanced, LTP eliminated
2 (0, 1, 2, 3) 1 0 0 (3, 3, 0, 5) LTD normalized, LTP largely restored
3 (0, 1, 2, 3) 0 1 0 (3, 3, 0, 0) LTD normalized, LTP is reversed to LTD
4 (0, 1, 2, 3) 0 0 1 (3, 0, 0, 4) LTD still enhanced, LTP partially restored
5 (0, 1, 2, 3) 1 1 0 (3, 3, 0, 3) LTD normalized, LTP still eliminated
6 (0, 1, 2, 3) 1 0 1 (3, 3, 0, 6) LTD normalized, LTP fully restored
7 (0, 1, 2, 3) 0 1 1 (3, 3, 0, 1) LTD normalized, LTP partially reversed to LTD
8 (0, 1, 2, 3) 1 1 1 (3, 3, 0, 4) LTD normalized, LTP partially restored
Abeta(1) pertains in all cases. Row 1 reiterates the unaltered Abeta effects from Table 2 Rows 5–8. None of the combinations alter the baseline AMPAR level.
The same results are obtainable with the MATLAB or Maude versions of the Aβ-synapse model.
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FIGURE 2 | The subset of interactions involved in PKA suppression of
LTD. Experiments suggest (see subsection Experimental Data on Basic
Mechanisms of LTP and LTD) that AC has a relatively high threshold and is
only activated (via CaM) at the high levels of Ca that produce LTP. Once
activated (via AC and cAMP), PKA suppresses LTD by inhibiting STEP, PP1,
and GSK3. PKA inhibits STEP and GSK3 directly, but inhibits PP1 indirectly
by activating PPI1 and by inhibiting GSK3, which would otherwise activate
PP1 via disinhibition through I2.
With Abeta(1), PDEblock by itself does not reduce the
LTD enhancement but it does slightly improve LTP (Table 5 Row
2). PDEblock does not alter the Ca level at any level of preSYN,
so the behavior of the model with Abeta(1) is largely the same
with PDEblock as without it. Specifically, the kinases and phos-
phatases take the LTD pattern at preSYN(1) and preSYN(2),
and PKA is activated and thwarts LTD at preSYN(3), whether
PDEblock is present or absent. But PDEblock boosts PKA
by 1, selectively when Ca surpasses the AC threshold (ACthr),
and this increases the PKA contribution to the AMPAR level at
preSYN(3), thus providing some improvement in LTP.
Combining PDEblock and proACT with Abeta(1) adds
some reduction in LTD enhancement to the improvement in LTP
due toPDEblock (Table 5Row 3).With or withoutPDEblock,
as explained above, PKA is activated at preSYN(3) and thwarts
LTD. PKA does this in part by suppressing STEP which, among
other functions, reduces the AMPAR level by 1. The added ben-
efit of proACT, which stimulates the proteosome, is that
it suppresses STEP at preSYN(1) and preSYN(2), thereby
boosting AMPAR by 1 at those levels. This does not reduce the
range of LTD with Abeta(1) but it does reduce the over-
all amount of LTD, and this could provide some benefit at the
behavioral level (see Discussion).
Combining PDEblock and PP1block with Abeta(1)
adds the same reduction in LTD enhancement to the improve-
ment in LTP due to PDEblock (Table 5 Row 4), but it does
that through a different mechanism. PP1, among other func-
tions, boosts GSK3 by 1, and GSK3, like STEP, also reduces
the AMPAR level. By blocking PP1, PP1block also reduces
the GSK3 level by 1 and this increases the AMPAR level by
1 at preSYN(1) and preSYN(2). Crucially, proACT and
PP1block increase AMPAR through different mechanisms:
proACT suppresses STEP thereby increasing the AR2 subunit of
AMPAR by 1, while PP1block suppresses GSK3 thereby increas-
ing the KLC2 component of AMPAR by 1. Because these factors
work through different pathways their effects do not occlude one
another but sum together, and combining PDEblock with both
proACT and PP1block further reduces the LTD enhancement
at preSYN(1) and preSYN(2) (Table 5 Row 5).
With Abeta(1), combining PDEblock with proACT and
PKCact increases the AMPAR baseline, but it provides the
potentially beneficial effects of reducing the range of LTD while
increasing both the level and range of LTP (Table 5 Row 6).
By keeping PKC active, a side effect of PKCact is to raise the
AMPAR baseline because, among other functions, PKC directly
increases the AMPAR level by increasing the AR1 subunit level.
This contribution is cancelled when PP1 is active, which occurs
at preSYN(1) with this combination (PDEblock, proACT,
and PKCact). The main effect of PKCact in conjunction with
proACT is to increase the Ca level by 1 at all levels of preSYN
greater than 0. This occurs because PKC activates Pyk2, while
the proteosome inactivates STEP, and those effects together
activate Src, which increases the NMDAR conductance for Ca.
That does not appreciably change the behavior of the model at
preSYN(1), and the LTD kinase/phosphatase pattern predom-
inates there except that STEP is 0 due to proACT. However,
at preSYN(2) the Ca level is now sufficient to cross the AC
threshold and this activates PKA, which attains a higher level than
normal because of PDEblock. This promotes LTP. The same
occurs at preSYN(3) because of PDEblock (see above in this
subsection for effects of PDEblock).
Combining PDEblock with proACT, PKCact, and
PP1block also raises the AMPAR baseline and increases both
the level and range of LTP, but it reduces LTD at preSYN(1)
(Table 5 Row 7). It does this in two ways: it suppresses GSK3
thereby increasing the KLC2 component of AMPAR by 1 (see
above in this subsection for effects of PP1block), and simply
by blocking PP1 it prevents PP1 from canceling the PKC
contribution to the AR1 subunit that is brought about through
PKCact. With proACT suppressing STEP and increasing the
AR2 subunit by 1 (see above in this subsection for effects of
proACT), the net activation of AMPAR at preSYN(1) is 3.
While this combination does not return synaptic plasticity to
normal, these compound effects may offer some benefit in terms
of reducing the deleterious consequences of Aβ for synaptic
plasticity at the behavioral level (see Discussion).
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EFFECTS OF COMPOUNDS THAT TARGET RECEPTORS AND SIGNALING
MOLECULES TOGETHER
In the presence of Abeta [i.e., Abeta(1)], using AChRnorm
by itself normalizes LTD and almost fully restores LTP (Table 4
Row 2). Using AChRnorm in conjunction with PDEblock pro-
vides full normalization of LTD and full restoration of LTP with
no change in AMPAR baseline (perfect plasticity; Table 6 Row 2).
This occurs because PDEblock boosts PKA, and so also boosts
the contribution of PKA to the AMPAR level, but only after AC
is activated at preSYN(3) and generates cAMP. Many other
combinations of AChRnorm and signaling compounds can also
change synaptic plasticity with Abeta(1) but no other such
combination (besides AChRnorm and PDEblock) also achieves
perfect plasticity.
Using mGRblock by itself with Abeta(1) prevents LTD at
preSYN(1) but allows it at preSYN(2) and, aberrantly, allows
LTD also at preSYN(3) (Table 4 Row 3). There is no com-
pound for modification of signaling molecules in the model that
in conjunction with mGRblock gives normal AMPAR baseline
with normal LTD [i.e., LTD only at preSYN(2)], and with LTP
greater than AMPAR baseline at preSYN(3). Some combina-
tions provide improvement in LTP but at the expense of base-
line increase and LTD dysregulation. Two noteworthy examples
involve combinations of signaling modifiers that already improve
synaptic plasticity without mGRblock. Combining PDEblock,
PKCact, and proACT raises the AMPAR baseline but produces
a small, net LTP improvement at preSYN(3). This combina-
tion produces no net reduction in LTD at preSYN(1) but at
preSYN(2) it converts LTD to LTP (Table 5 Row 6). Combining
PDEblock, PKCact, proACT, and mGRblock (i.e., adding
mGRblock to the mix) converts plasticity at preSYN(2) back
to LTD, thereby restricting LTP to preSYN(3) (Table 6 Row 3).
The same phenomenon occurs for the combination PDEblock,
PKCact, proACT, and PP1block, which again provides net
improvement in LTP at preSYN(3) despite raising AMPAR
baseline but also causes LTP to occur, aberrantly, at preSYN(2)
(Table 5 Row 7). Of potential benefit (see Discussion), this com-
bination reduces the amount of LTD at preSYN(1) (again
Table 5 Row 7). As in the previous case (Table 6 Row 3), the
effect of adding mGRblock to this combination is to convert
LTP back to LTD at preSYN(2), thereby restricting LTP to
preSYN(3) (Table 6 Row 4). mGRblock achieves this effect by
lowering Ca at all preSYN levels greater than 0 (see subsection
Effects of Compounds that Modify Receptor Function). Other
combinations of mGRblock and signaling molecule modifica-
tion compounds achieve the same reduction in LTD enhancement
and improvement of LTP but further raise AMPAR baseline.
With Abeta(1), using TrkBnorm by itself provides a slight
improvement in LTP but does not diminish LTD enhancement
(Table 4 Row 4). As with mGRblock, there is no combina-
tion of TrkBnorm with signaling modification compounds that
gives more LTD for preSYN(2) than for preSYN(1) and
gives any improvement in LTP at preSYN(3). However, by
boosting the AMPAR level at preSYN(3), TrkBnorm can also
improve LTP and reduce LTD enhancement in combination
with signaling molecule modifiers. By themselves, PP1block or
proACT reduce the LTD enhancement due to Abeta by reduc-
ing the reduction in AMPAR level each by 1 at preSYN(1)
and preSYN(2). Combining TrkBnorm with PP1block and
proACT provides the same incremental LTP improvement as
Table 5 | Effects on synaptic plasticity of compounds that modify signaling molecules.
Row preSYN PDEblock PKCact PP1block proACT AMPAR Effect
1 (0, 1, 2, 3) 0 0 0 0 (3, 0, 0, 3) Abeta dysregulation:
LTD enhanced (and range expanded)
LTP eliminated (suppressed)
2 (0, 1, 2, 3) 1 0 0 0 (3, 0, 0, 4) LTD enhancement unchanged
LTP partially restored
3 (0, 1, 2, 3) 1 0 0 1 (3, 1, 1, 4) LTD enhancement reduced
LTP partially restored
4 (0, 1, 2, 3) 1 0 1 0 (3, 1, 1, 4) LTD enhancement reduced
LTP partially restored
5 (0, 1, 2, 3) 1 0 1 1 (3, 2, 2, 4) LTD enhancement further reduced
LTP partially restored
6 (0, 1, 2, 3) 1 1 0 1 (4, 1, 5, 5) AMPAR baseline increased
LTD shifted to lower level
LTP partially restored but LTP range expanded
7 (0, 1, 2, 3) 1 1 1 1 (4, 3, 5, 5) AMPAR baseline increased
LTD shifted to lower level and reduced
LTP partially restored but LTP range expanded
Abeta(1) pertains in all cases. Row 1 reiterates the unaltered Abeta effects from Table 2 Rows 5–8. The same results are obtainable with the MATLAB or Maude
versions of the model.
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TrkBnorm alone and also sums the reductions in LTD enhance-
ment due to PP1block and proACT (Table 6Row 5). The com-
bination PDEblock, proACT, and PP1block (Table 5 Row 5)
produces the same change in plasticity (i.e., slight LTP improve-
ment and reduction of LTD enhancement) as the combination
TrkBnorm, PP1block, and proACT (Table 6 Row 5), and the
union of these combinations, which is TrkBnorm, PDEblock,
PP1block, and proACT, achieves the same LTD reduction with
more improvement in LTP (Table 6 Row 6). Other combina-
tions of TrkBnormwith signalingmodifiers further raise AMPAR
baseline but, relative to that baseline, do not give better reduction
of LTD enhancement or better LTP improvement.
As explained in subsection Effects of Compounds that Modify
Signaling Molecules, the main effect of the combination of
PKCact and proACT with Abeta(1) is to increase the Ca
level at all levels of preSYN greater than 0. Another bene-
fit of proACT is inactivation of STEP, while a side effect of
PKCact is augmentation of the AMPAR baseline. The upshot of
this is restriction of LTD to preSYN(1), with an augmented
AMPAR baseline at all other preSYN levels. Adding TrkBnorm
to this duo, yielding the combination TrkBnorm, PKCact,
and proACT, adds a slight LTP improvement at preSYN(3)
(Table 6 Row 7). The combination PKCact, proACT, and
PP1block produces effects similar to PKCact and proACT
but, by suppressing PP1, PP1block reduces the amount of
LTD that is limited by the other two factors to preSYN(1).
Now adding TrkBnorm to this trio, yielding the combination
TrkBnorm, PKCact, proACT, and PP1block, adds an incre-
mental LTP improvement at preSYN(3) (Table 6Row 8).While
these behaviors are far from normal, they at least move the dysreg-
ulated plasticity due to Abeta back toward normal and in ways
that could be therapeutically significant (see Discussion).
DISCUSSION
The main purpose of the model is to suggest combinations of
compounds that could be tested for efficacy in normalizing synap-
tic plasticity in the presence of Aβ. Validated combinations could
be considered for development as pharmaceutical treatments. An
ancillary purpose is to provide a view of the operation of the
molecular machinery of the synapse and how that is affected by
Aβ. For example, in the normal synapse (i.e., in the absence of
Aβ) the model suggests that PKA is responsible for keeping STEP
(and other key LTD drivers) inactive when Ca is high enough to
elicit LTP (see Figure 2). Exploration of this interaction could fur-
ther elucidate the role of STEP in overall synaptic function (Moult
et al., 2006; Zhang et al., 2008). In the diseased synapse (i.e., in
the presence of Aβ), the model suggests that the action of PKA
is instrumental in preventing LTD from occurring at all non-zero
levels of presynaptic activity including that which would evoke
LTP in the normal synapse. The model further suggests that PKA
is the mediator that keeps the diseased synapse at least at baseline
at high levels of presynaptic activity.
Table 6 | Effects on synaptic plasticity of compounds that modify receptors or signalers.
Row preSYN AChRnorm mGRblock TrkBnorm PDEblock PKCact PP1block proACT AMPAR Effect
1 (0, 1, 2, 3) 0 0 0 0 0 0 0 (3, 0, 0, 3) Abeta dysregulation:
LTD range expanded
LTP eliminated
2 (0, 1, 2, 3) 1 0 0 1 0 0 0 (3, 3, 0, 6) LTD normalized
LTP fully restored
3 (0, 1, 2, 3) 0 1 0 1 1 0 1 (4, 1, 1, 5) AMPAR baseline increased
LTD enhancement unchanged
LTP partially restored
4 (0, 1, 2, 3) 0 1 0 1 1 1 1 (4, 3, 3, 5) AMPAR baseline increased
LTD enhancement reduced
LTP partially restored
5 (0, 1, 2, 3) 0 0 1 0 0 1 1 (3, 2, 2, 4) LTD enhancement reduced
LTP partially restored
6 (0, 1, 2, 3) 0 0 1 1 0 1 1 (3, 2, 2, 5) LTD enhancement reduced
LTP further restored
7 (0, 1, 2, 3) 0 0 1 0 1 0 1 (4, 1, 4, 5) AMPAR baseline increased
LTD shifted to lower level
LTP partially restored
8 (0, 1, 2, 3) 0 0 1 0 1 1 1 (4, 3, 4, 5) AMPAR baseline increased
LTD shifted and reduced
LTP partially restored
Abeta(1) pertains in all cases. Row 1 reiterates the unaltered Abeta effects from Table 2 Rows 5–8. The same results are obtainable with the MATLAB or Maude
versions of the model.
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The model provides an initial framework in which to under-
stand how various drugs and drug combinations might operate
in the diseased synapse. The model suggests that normalization
of nAChR function may be the most effective way to counter-
act the adverse effects of Aβ on synaptic plasticity, lending some
modeling support to the suggestion that disordered nAChR func-
tion is the main route by which Aβ dysregulates synaptic plasticity
(Wang et al., 2000; Snyder et al., 2005; Shankar et al., 2008). Some
studies suggest that certain compounds, such as S 24795, can
actually displace Aβ from the nAChR and restore its normal func-
tion (Chen et al., 2006; Wang et al., 2009). The model identifies
these compounds as exciting candidates for further drug develop-
ment, either alone or in combination with other compounds such
as phosphodiesterase inhibitors.
The Aβ-synapse model is based on findings from the literature,
mainly from in vitro experiments using brain slice preparations.
Overall model behavior is consistent with the observation from
whole animals and humans that Aβ overproduction leads to cog-
nitive impairment and specifically to deficits in learning and
memory. As a data-driven model, the Aβ-synapse model does
not rely on unproven assumptions, and it is readily testable
using the same techniques that were used to gather the data
on which the model is based (see below in this section). Of
course, the Aβ-synapse model is also limited by the available
data, which is incomplete, obtained using diverse and unstan-
dardized preparations, and in a very few cases may in fact be
wrong. Yet researchers have no option other than to generate their
hypotheses on the basis of available data. The main advantage
of the model is to gather together, in a precisely defined man-
ner, a much larger set of data than possibly could be held in
mind by individual researchers, and to determine the aggregate
implications of those data through computational simulations
and analyses. The result is a large number of experimentally
testable predictions that are based on much of what is cur-
rently known concerning the adverse effects of Aβ on synaptic
plasticity.
Most in vitro studies of Aβ-induced dysregulation of synap-
tic plasticity concern only one mechanism and focus on LTP
suppression without regard for the LTD enhancement that is
also induced by Aβ (see subsection Experimental Data on Aβ
Effects on Synaptic Plasticity). The Aβ-synapse model takes a
much broader view and considers many mechanisms, and the
effects of many compounds, on both LTP and LTD. The model
represents the results of many labs, each using different prepara-
tions, and it does not conform in detail to any one preparation.
Instead, the model adopts a general framework in anticipation
of the standardization of preparations that will be required for
the achievement of a global understanding of the effects of Aβ on
synaptic plasticity.
Even in its initial form, the model offers a perspective on
potential multidrug therapies that could protect synapses from
the adverse effects of Aβ. For example, many individual com-
pounds that improve LTP in vitro also improve learning and
memory in vivo (see subsection Experimental Data on Aβ Effects
on Synaptic Plasticity). The model suggests that some of these
single compoundsmay not also reduce Aβ-induced LTD enhance-
ment (see Results), in which case the LTP increase alone is enough
to cause the observed benefit on the behavioral level. The model
suggests many combinations that may be more effective than sin-
gle compounds in normalizing the plasticity of the AD synapse
(see Results), and it is reasonable to suppose that they may
provide further behavioral benefit as well.
One aim of this initial model is to provide a framework that
could be expanded into a comprehensive view of the AD synapse.
An obvious but challenging area of expansion is into mechanisms
of LTP and LTD that involve new protein synthesis. Other impor-
tant expansion areas include those that address practical aspects
of drug design such as the relative efficacies and pharmacokinet-
ics of specific compounds, and issues specific to human biology
and pharmacology. The data-driven Aβ-synapsemodel is expand-
able by design, because it is based not on preconceived ideas but
directly on data concerning the interactions among molecular
species and subcellular organelles as determined experimentally.
Because the model is based on data that are almost entirely qual-
itative, elements in the model are restricted to take one of a few
integer levels that reflect relative increases or decreases in activity
(see subsection Computational Representation, Simulation, and
Analysis). Because of the discrete nature of the model, changes
in parameters such as thresholds would have drastic effects
and would cause model behavior to disagree with observation.
However, the model parameters that influence the interactions,
as well as the specifications of the interactions themselves, are all
subject to revision on the basis of the results of tests of model
predictions.
Another aim of the initial model is to initiate a computa-
tional/experimental interaction in which model predictions are
tested by an array of experimentalists working in different labs
(but perhaps eventually using a standardized preparation). The
test results would be used to correct or confirm, refine, and
expand the model, the model would be used to generate new
predictions, and that cycle would continue, producing a model
of ever increasing explanatory and predictive power. Most of the
data for the initial Aβ-synapse model was derived from in vitro
experiments using brain slice preparations, and the predictions
of the initial model would be most effectively tested using the
brain slice. It would also be reasonable to start with a stan-
dard preparation in which protein synthesis is inhibited, and
then add protein synthesis mechanisms after the model and
the data achieve complete agreement without them. There is
no a priori reason to expect any limitations on the growth of
the model. Even with its focus trained on the synaptic level,
it should be possible to expand the model by incorporating
enough extra-synaptic influences such as levels of neuromodu-
lators, hormones, and cytokines, so that model predictions will
be relevant on the whole-organism level and can be tested on
that level.
The Aβ-synapse model is readily expandable, fully adjustable,
and highly testable. Every modeling result is essentially a mod-
eling prediction, and every experimental result that is not
confirmatory can be used to correct the model. As such the
Aβ-synapse model will serve as a valuable adjunct to experi-
ment in the search for treatments for AD, but it will also have
value in its own right as a conceptual tool. By combining imper-
ative (i.e., MATLAB) and declarative (i.e., Maude) computer
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modeling modalities, the initial Aβ-synapse model illustrates
how complex neurobiological and neuropathological processes
can be represented, simulated, and analyzed computationally
to gain deeper understanding of basic mechanisms, new ratio-
nales for multitarget drug design, and new insights into possible
treatments.
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